AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33749321
Drug: OB-002H gel
RxNorm normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OB-002H gel (5 vaginal daily doses)
Trial: 33749321
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo (5 vaginal daily doses)
Trial: 33749321
Drug: OB-002H gel
RxNorm normalized name: Obe-cel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OB-002H gel
Trial: 35315622
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion
Trial: 38107550
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (IVIG)
Trial: 33213527
Drug: Levamlodipine 5
RxNorm normalized name: levamlodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamlodipine 5 mg (fasted)
Trial: 33213527
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg (fasted)
Trial: 33213527
Drug: Levamlodipine 5
RxNorm normalized name: levamlodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamlodipine 5 mg (fed)
Trial: 34706311
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneous every 6 months) added to intensive urate-lowering therapy (ULT)
Trial: 34706311
Drug: Intensive urate-lowering
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intensive urate-lowering therapy (ULT) alone
Trial: 32011496
Drug: Phellinus linteus
RxNorm normalized name: PHELLINUS LINTEUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phellinus linteus (PL) 2000 mg
Trial: 32011496
Drug: Phellinus linteus
RxNorm normalized name: PHELLINUS LINTEUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phellinus linteus (PL) 1000 mg
Trial: 36501004
Drug: 392 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 392 mg/day of blackcurrant powder (low blackcurrant, BC, group, n = 16)
Trial: 36501004
Drug: 784 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 784 mg/day of blackcurrant powder (high BC group, n = 11)
Trial: 34185664
Drug: Mucoadhesive tablet
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mucoadhesive tablet without the active ingredient
Trial: 32977777
Drug: Surgical conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical conditions (treatment)
Trial: 34373362
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (sodium alginate)
Trial: 32406989
Drug: Standard recommendation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard recommendation on oral rehydration solution use
Trial: 34915725
Drug: Group Interpersonal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Interpersonal Psychotherapy (IPT-G)
Trial: 32912218
Drug: Usual discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual discharge care and monthly social call
Trial: 34473302
Drug: Higher kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher kidney injury molecule‐1 (KIM-1)
Trial: 33826436
Drug: IOPTx™ system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOPTx™ system (wearable electroceutical treatment)
Trial: 39215063
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g of milk chocolate
Trial: 34739635
Drug: Molecular-based recommended
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular-based recommended therapy (MBRT) proposed after molecular profiling
Trial: 34739635
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of MBRT
Trial: 33673567
Drug: Received caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Received caffeine (3 mg/kg)
Trial: 33673567
Drug: Placebo (cellulose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose, 3 mg/kg)
Trial: 38829619
Drug: Collaborative Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative Care (CC)
Trial: 34313619
Drug: Methylphenidate (short-acting,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (short-acting, twice daily)
Trial: 32900564
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg 2 hours after TKA, followed by 200 mg 6 hours later
Trial: 32900564
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 400 mg of celecoxib the second day after surgery
Trial: 33785496
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection
Trial: 34286867
Drug: Laser-assisted scaling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted scaling and root planing (L-SRP)
Trial: 32551725
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy
Trial: 34801917
Drug: Midodrine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (10 mg every 8 hours)
Trial: 34170908
Drug: IV furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV furosemide infusion
Trial: 34170908
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo infusion
Trial: 32907500
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg donafenib
Trial: 32907500
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg donafenib
Trial: 34106357
Drug: Pivotal Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pivotal Response Treatment (PRT)
Trial: 35569283
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (n = 149)
Trial: 35569283
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (n = 151)
Trial: 32167038
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of oral cholera vaccine (OCV)
Trial: 38729426
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: 33977284
Drug: RTB101 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTB101 10 mg once daily
Trial: 33977284
Drug: RTB101 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTB101 10 mg in combination with everolimus 0.1 mg once daily
Trial: 34662695
Drug: Tomatis sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomatis sound therapy (TST)
Trial: 35305913
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol 1 g infusion
Trial: 35613998
Drug: SBRT (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT (8 Gy x 3 fractions) plus systemic therapy
Trial: 37596449
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy alone
Trial: 35696837
Drug: Verbal-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal-based cognitive behavioral group therapy (VB-CBGT)
Trial: 35124183
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years
Trial: 33382352
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of omega-3 supplementation
Trial: 32486840
Drug: Guideline-concordant antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-concordant antibiotics (amoxicillin and azithromycin)
Trial: 36114901
Drug: Denosumab treatment
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab treatment
Trial: 34045222
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of PGA therapy
Trial: 34045222
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of PGA therapy after cataract surgery (CPGA)
Trial: 33745587
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation protocol in Rotterdam: commercial vitamins and trace elements via 8-hour infusion and electrolytes continuously over 24 hours.
Trial: 35777921
Drug: InSpace implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InSpace implant
Trial: 34571624
Drug: Ologen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ologen implant
Trial: 34750705
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray in sitting position (Group A)
Trial: 34750705
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray in supine position (Group B)
Trial: 33814231
Drug: 3-dose 20
RxNorm normalized name: Hep A, ped/adol, 3 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose 20 μg recombinant hepatitis B vaccine
Trial: 33814231
Drug: 3-dose 60
RxNorm normalized name: Hep A, ped/adol, 3 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose 60 μg recombinant hepatitis B vaccine
Trial: 34563277
Drug: Matrix-M-adjuvanted quadrivalent
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix-M-adjuvanted quadrivalent nanoparticle influenza vaccine (qNIV)
Trial: 32057673
Drug: Low-dose HCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose HCG from Day 7 until at least three follicles reached 17 mm or more
Trial: 32057673
Drug: Conventional ovarian
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ovarian stimulation with highly purified HMG injections
Trial: 616119287
Drug: Retixoft (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retixoft (300 mg alpha-lipoic acid, 1.1 mg vitamin B1, 1.4 mg vitamin B2, 25 mg rutoside) for 3 months
Trial: 34672925
Drug: Augmented Reality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented Reality Exposure Therapy (ARET)
Trial: 38448081
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOACs)
Trial: 38199288
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 μg
Trial: 35264104
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment without stimulation.
Trial: 32838539
Drug: Telehealth cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth cognitive behavioral therapy for insomnia (CBT‐CI)
Trial: 37352528
Drug: Neoadjuvant intensity
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant intensity modulated radiation therapy (18 Gy with fractionated doses of 3 Gy) followed by surgery 4 weeks later
Trial: 33808137
Drug: Wrist stabilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wrist stabilization exercise + taping therapy (WSE + TT)
Trial: 33525659
Drug: Biological control
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological control
Trial: 36862472
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine
Trial: 33121372
Drug: FF/UMEC/VI 100/62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC/VI 100/62.5/25 µg
Trial: 33676601
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg once every 3 weeks for 35 cycles
Trial: 32548677
Drug: Subcutaneous Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Immunotherapy (SCIT)
Trial: 33819508
Drug: Subcutaneous Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)
Trial: 36882015
Drug: Sublingual Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual Immunotherapy (SLIT)
Trial: 35226081
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus oxaliplatin (SOX) - 130 mg/m2 oxaliplatin on day 1 and 80 to 120 mg/d S-1 orally daily for 2 weeks, 6 cycles (2-4 preoperative and 2-4 postoperative)
Trial: 35226081
Drug: Fluorouracil, leucovorin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil, leucovorin, and oxaliplatin (FOLFOX) - 130 mg/m2 oxaliplatin, 400 mg/m2 fluorouracil, 400 mg/m2 leucovorin, and 2400 mg/m2 fluorouracil as 46-hour infusion on day 1, 6 cycles (2-4 preoperative and 2-4 postoperative)
Trial: 33484775
Drug: Elafibranor 120
RxNorm normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elafibranor 120 mg
Trial: 32110986
Drug: 140 mg
RxNorm normalized name: caffeine 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 mg of Zynamite® combined with 140 mg of quercetin
Trial: 38300408
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg
Trial: 33285745
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus Pirfenidone capsule
Trial: 35397798
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide at a dose of 800 μg twice a day plus usual care
Trial: 35107023
Drug: TLR4 neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR4 neutralizing antibodies
Trial: 32958702
Drug: Lenalidomide concurrent
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide concurrent with PCV13 vaccine (arm A)
Trial: 32958702
Drug: Lenalidomide sequential
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide sequential to PCV13 vaccine (arm B)
Trial: 35384387
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone (100 mg)
Trial: 32673037
Drug: Transdiagnostic behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic behavior therapy (TBT)
Trial: 35297288
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (standard treatment)
Trial: 37497816
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy alone
Trial: 33977560
Drug: Varenicline doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline doses (0.25 mg per day, 0.25 mg b.i.d., 0.5 mg b.i.d., and 1.0 mg b.i.d.)
Trial: 38554938
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg
Trial: 36206950
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative management with GDMT alone and angiography reserved for failure of medical therapy
Trial: 33797063
Drug: Bafiertam™ (MMF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bafiertam™ (MMF) 190 mg as 2 × 95 mg delayed-release capsules
Trial: 34350569
Drug: Potassium (K)
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium (K) at 11.6 mmol L‐1
Trial: 34350569
Drug: Cadmium (Cd)
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadmium (Cd) at 1.5 mmol L‐1
Trial: 33785077
Drug: Exergaming (stepping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exergaming (stepping exergame program, 8 weeks, 3 times weekly, 15 min per session)
Trial: 35536764
Drug: Febuxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40 or 80 mg, based on sUA at Week 2)
Trial: 34622721
Drug: Propolis (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis (250 mg/two times per day for three months)
Trial: 33860579
Drug: Taxane/platinum therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane/platinum therapy (paclitaxel + carboplatin)
Trial: 33860579
Drug: Taxane/platinum therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane/platinum therapy (paclitaxel + carboplatin) with additional docetaxel and nedaplatin
Trial: 38847412
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg
Trial: 35691323
Drug: Ustekinumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (6 mg/kg IV on day 0, then 90 mg SC every 8 weeks)
Trial: 35691323
Drug: Adalimumab (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (160 mg on day 0, 80 mg at 2 weeks, then 40 mg SC every 2 weeks)
Trial: 36008759
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg/h continuous infusion (group D2)
Trial: 36008759
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg over 10 min and 0.5 μg/kg/h continuous infusion (group D3)
Trial: 32000820
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone 10 mg three times daily
Trial: 33630863
Drug: Stockholm3 Model
RxNorm normalized name: Stockholm tar
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stockholm3 Model (S3M) test as a reflex test for PSA ≥ 2 ng/mL
Trial: 33630863
Drug: Stockholm3 Model
RxNorm normalized name: Stockholm tar
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stockholm3 Model (S3M) test with reflex thresholds of 1 ng/mL
Trial: 34816601
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) pretreatment to Dialectical Behaviour Therapy Skills Training (DBT-ST); 4-week group MET pretreatment followed by 12-week DBT-ST
Trial: 34816601
Drug: Dialectical Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behaviour Therapy Skills Training (DBT-ST) only; 12-week DBT-ST
Trial: 33170417
Drug: Meropenem (MEPM)
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem (MEPM) at 120 mg/kg/day as a 1-h drip infusion 3 times a day
Trial: 33170417
Drug: Piperacillin/tazobactam (PIPC/TAZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (PIPC/TAZ) at 360 mg/kg/day as a 1-h drip infusion 4 times a day
Trial: 35129469
Drug: N-Acetyl-Cysteine (NAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-Acetyl-Cysteine (NAC) 1200 mg twice-daily for up to 5 days postoperatively
Trial: 35101523
Drug: Oral rapamycin
RxNorm normalized name: kanamycin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rapamycin (6 mg) prior to IV ketamine (0.5 mg/kg)
Trial: 34069369
Drug: Smart-ring CC
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart-ring CC feedback
Trial: 35964909
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg, oral, once a day)
Trial: 35964909
Drug: Placebo (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, once a day)
Trial: 37865896
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg/d)
Trial: 32476255
Drug: linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin (5 mg)
Trial: 32476255
Drug: glimepiride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glimepiride (1 mg)
Trial: 36944357
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg daily
Trial: 33826539
Drug: High-sensitivity CRP
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity CRP ≥2 mg/dL
Trial: 33387165
Drug: Study without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study without Stress (Cognitive Behavioural Therapy program)
Trial: 35964947
Drug: Low-flow anesthesia
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow anesthesia (Group L)